Therapeutic Potential of Lebrikizumab in the Treatment of Atopic Dermatitis.

Tiffany Y Loh Jennifer L Hsiao Vivian Y Shi

Published in: Journal of asthma and allergy (2020)

Lebrikizumab appears to be a promising emerging targeted biologic for the treatment of moderate-to-severe AD. Further Phase III studies investigating optimal dosing regimens and safety profile are needed.

Keyphrases

phase iii
clinical trial
atopic dermatitis
rheumatoid arthritis
early onset
cancer therapy
combination therapy
phase ii
smoking cessation